---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-201161"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T12:57:55.971205+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Karyopharm Q2 total rev $37.6M; net loss $32.6M; cuts workforce 20%, guides FY rev $145-160M

## Summary
- Q2 total rev $37.6M (down 5% YoY); net loss $32.6M ($0.29/sh) improved from $49.1M ($0.62/sh).
- U.S. XPOVIO net product rev $28.5M (flat YoY); FY 2023 guidance: total rev $145-160M, XPOVIO $110-125M.
- Workforce cut ~20%; non-GAAP R&D+SG&A guidance lowered to $240-255M; cash runway extended into late 2025.
- Initiated pivotal Phase 3 (XPORT-MF-034) of selinexor+ruxolitinib in JAKi-naïve myelofibrosis; Fast Track from FDA.
- Revenue Interest Financing amended: cap raised to 195%, warrants for 250k shares at $2.25, payment date extended to June 2025.

## SEC filing metadata
- accession: 0001193125-23-201161
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312523201161/0001193125-23-201161-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312523201161/d542880d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-201161
- JSON: https://secwatch.observer/filing/0001193125-23-201161.json
- Plain text: https://secwatch.observer/filing/0001193125-23-201161.txt

## Key facts
- Earnings Releases
  Karyopharm Therapeutics Inc. reported the quarter ended June 30, 2023 results: revenue $37.6 Million. Guidance reaffirmed.
  - Period: the quarter ended June 30, 2023
  - Revenue: $37.6 Million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress – Achieved Second Quarter 2023 Total Revenue of $37.6 Million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312523201161/0001193125-23-201161-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.